AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives

References

• Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11(2):56–63.
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19–24.
   Google Scholar
• Fycompa Summary of Product Characteristics. [cited 2017 Jul 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf
   Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4:18–61.
   PubMed Web of Science ®Google Scholar
• Russo E, Gitto R, Citraro R, et al. New AMPA antagonists in epilepsy. Expert Opin Investig Drugs. 2012;21(9):1371–1389.
   PubMed Web of Science ®Google Scholar
• Wilcox KS, Peter JW, Dichter MA. Chapter 22: excitatory synaptic transmission. In: Engel J Jr, Pedley TA, editors. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia, USA: Wolters Kluwer Health, Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Citraro R, Aiello R, Franco V, et al. Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. Expert Opin Ther Targets. 2014;18(3):319–334.
   PubMed Web of Science ®Google Scholar
• During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet. 1993;341(8861):1607–1610.
   PubMed Web of Science ®Google Scholar
• Lopes MW, Soares FM, de Mello N, et al. Time-dependent modulation of AMPA receptor phosphorylation and mRNA expression of NMDA receptors and glial glutamate transporters in the rat hippocampus and cerebral cortex in a pilocarpine model of epilepsy. Exp Brain Res. 2013;226(2):153–163.
   PubMed Web of Science ®Google Scholar
• Gidal BE, Laurenza A, Hussein Z, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84(19):1972–1980.
   PubMed Web of Science ®Google Scholar
• Ekonomou A, Smith AL, Angelatou F. Changes in AMPA receptor binding and subunit messenger RNA expression in hippocampus and cortex in the pentylenetetrazole-induced ‘kindling’ model of epilepsy. Brain Res Mol Brain Res. 2001;95(1–2):27–35.
   PubMedGoogle Scholar
• Rakhade SN, Zhou C, Aujla PK, et al. Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. J Neurosci. 2008;28(32):7979–7990.
   PubMed Web of Science ®Google Scholar
• Rakhade SN, Fitzgerald EF, Klein PM, et al. Glutamate receptor 1 phosphorylation at serine 831 and 845 modulates seizure susceptibility and hippocampal hyperexcitability after early life seizures. J Neurosci. 2012;32(49):17800–17812.
   PubMed Web of Science ®Google Scholar
• Zilles K, Qü MS, Köhling R, et al. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography. Neuroscience. 1999;94(4):1051–1061.
   PubMed Web of Science ®Google Scholar
• Palomero-Gallagher N, Schleicher A, Bidmon HJ, et al. Multireceptor analysis in human neocortex reveals complex alterations of receptor ligand binding in focal epilepsies. Epilepsia. 2012;53(11):1987–1997.
   PubMed Web of Science ®Google Scholar
• Barygin OI. Inhibition of calcium-permeable and calcium-impermeable AMPA receptors by perampanel in rat brain neurons. Neurosci Lett. 2016;633:146–151.
   PubMed Web of Science ®Google Scholar
• Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331–1340.
   PubMed Web of Science ®Google Scholar
• Citraro R, Leo A, Franco V, et al. Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior. Epilepsia. 2017;58(2):231–238.
   PubMed Web of Science ®Google Scholar
• Hanada T, Ido K, Kosasa T. Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect. 2014;2(5):e00063.
   PubMedGoogle Scholar
• Zwart R, Sher E, Ping X, et al. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. J Pharmacol Exp Ther. 2014;351(1):124–133.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012;125(1):8–15.
   PubMed Web of Science ®Google Scholar
• Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126(4):263–269.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79:589–596.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117–125.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–1415.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013;54(1):126–134.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55(7):1058–1068.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481–1489.
   PubMed Web of Science ®Google Scholar
• Hsu WW, Sing CW, He Y, et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs. 2013;27(10):817–827.
   PubMed Web of Science ®Google Scholar
• Gitaí DL, Martinelli HN, Valente V, et al. Increased expression of GluR2-flip in the hippocampus of the Wistar audiogenic rat strain after acute and kindled seizures. Hippocampus. 2010;20(1):125–133.
   PubMed Web of Science ®Google Scholar
• Glauser T, Laurenza A, Yang H, et al. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: a phase III post-hoc analysis. Epilepsy Res. 2016;119:34–40.
   PubMed Web of Science ®Google Scholar
• Leppik IE, Wechsler RT, Williams B, et al. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216–220.
   PubMed Web of Science ®Google Scholar
• Ettinger AB, LoPresti A, Yang H, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252–1263.
   PubMed Web of Science ®Google Scholar
• Yang H, Laurenza A, Williams B, et al. Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Epilepsy Res. 2015;114:122–130.
   PubMed Web of Science ®Google Scholar
• Leppik IE, Yang H, Williams B, et al. Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies. Epilepsia. 2017;58(1):51–59.
   PubMed Web of Science ®Google Scholar
• Vazquez B, Yang H, Williams B, et al. Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures. Epilepsia. 2015;56(7):e90–94.
   PubMed Web of Science ®Google Scholar
• Rosenfeld W, Conry J, Lagae L, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19(4):435–445.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Yang H, Piña-Garza JE, et al. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57(2):243–251.
   PubMed Web of Science ®Google Scholar
• Lagae L, Villanueva V, Meador KJ, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016;57(7):1120–1129.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Majid O, Nabangchang C, et al. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. Epilepsy Res. 2016b;127:126–134.
   PubMed Web of Science ®Google Scholar
• Toledo M, Gonzalez-Cuevas M, Miró-Lladó J, et al. Sleep quality and daytime sleepiness in patients treated with adjunctive perampanel for focal seizures. Epilepsy Behav. 2016;63:57–62.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology. 2015;85(11):950–957.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Hamer H, Trinka E, et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res. 2014;108(5):986–988.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Garcés M, López-González FJ, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res. 2016;126:201–210.
   PubMed Web of Science ®Google Scholar
• De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res. 2016;127:93–100.
   PubMed Web of Science ®Google Scholar
• Heyman E, Lahat E, Levin N, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol. 2017;59(4):441–444.
   Google Scholar
• Juhl S, Rubboli G. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience. Acta Neurol Scand. 2016;134(5):374–377.
   PubMed Web of Science ®Google Scholar
• Rohracher A, Kalss G, Leitinger M, et al. Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data. Ther Adv Neurol Disord. 2016;9(6):445–453.
   PubMed Web of Science ®Google Scholar
• Maurousset A, Limousin N, Praline J, et al. Adjunctive perampanel in refractory epilepsy: experience at tertiary epilepsy care center in tours. Epilepsy Behav. 2016;61:237–241.
   PubMed Web of Science ®Google Scholar
• Shah E, Reuber M, Goulding P, et al. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study. Seizure. 2016;34:1–5.
   PubMed Web of Science ®Google Scholar
• Kurth C, Kockelmann E, Steinhoff BJ. Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - a monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center. Seizure. 2016;45:47–51.
   PubMed Web of Science ®Google Scholar
• Singh K, Shah YD, Luciano D, et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study. Epilepsy Behav. 2016;61:41–45.
   PubMed Web of Science ®Google Scholar
• Snoeijen-Schouwenaars FM, Van Ool JS, Tan IY, et al. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav. 2017;66:64–67.
   PubMed Web of Science ®Google Scholar
• Huber B, Schmid G. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment. Epilepsy Behav. 2017;66:74–79.
   PubMed Web of Science ®Google Scholar
• Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016;62:132–135.
   PubMed Web of Science ®Google Scholar
• Crespel A, Gelisse P, Tang NP, et al. Perampanel in 12 patients with Unverricht-Lundborg disease. Epilepsia. 2017;58(4):543–547.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Bacher M, Kurth C, et al. Add-on perampanel in Lance-Adams syndrome. Epilepsy Behav Case Rep. 2016;6:28–29.
   PubMed Web of Science ®Google Scholar
• Maschio M, Sperati F, Dinapoli L, et al. Weight of epilepsy in brain tumor patients. J Neurooncol. 2014;118(2):385–393.
   PubMed Web of Science ®Google Scholar
• Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10(2):124–133.
   PubMed Web of Science ®Google Scholar
• de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia. 2011;59(8):1181–1189.
   PubMed Web of Science ®Google Scholar
• Oh MC, Kim JM, Safaee M, et al. Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells. PLoS One. 2012;7(10):e47846.
   PubMed Web of Science ®Google Scholar
• Buckingham SC, Campbell SL, Haas BR, et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011;17(10):1269–1274.
   PubMed Web of Science ®Google Scholar
• Marcus HJ, Carpenter KL, Price SJ, et al. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol. 2010;97(1):11–23.
   PubMed Web of Science ®Google Scholar
• Yuen TI, Morokoff AP, Bjorksten A, et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology. 2012;79(9):883–889.
   PubMed Web of Science ®Google Scholar
• Neal A, Yuen T, Bjorksten AR, et al. Peritumoural glutamate correlates with post-operative seizures in supratentorial gliomas. J Neurooncol. 2016;129(2):259–267.
   PubMed Web of Science ®Google Scholar
• Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 2009;11(3):260–273.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009;27(25):4155–4161.
   PubMed Web of Science ®Google Scholar
• Cunningham MO, Chatterjee K, Nangal V, et al. Use of perampanel in brain tumour related epilepsy: evidence from ex vivo studies in human peritumoural neocortex. Abstract presented at Society of British Neurological Surgeons meeting, 2016. Br J Neurosurg. 2016;30:130–186.
   PubMedGoogle Scholar
• Rösche J, Piek J, Hildebrandt G, et al. Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation. Fortschr Neurol Psychiatr. 2015;83(5):286–289.
   PubMed Web of Science ®Google Scholar
• Maschio M, Zarabla A, Maialetti A, et al. Perampanel in add-on: effect on EEG background activity and efficacy on seizure control in patients with brain tumour-related epilepsy: preliminary data. Epilepsia. 2016;57(Suppl.2):P246.
   Google Scholar
• Vecht C, Duran-Peña A, Houillier C, et al. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol. 2017 May 10.
   PubMed Web of Science ®Google Scholar
• Palleria C, Coppola A, Citraro R, et al. Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis. Expert Opin Pharmacother. 2015;16(15):2355–2371.
   PubMed Web of Science ®Google Scholar
• Russmann V, Salvamoser JD, Rettenbeck ML, et al. Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy. Epilepsia. 2016;57(4):638–647.
   PubMed Web of Science ®Google Scholar
• Jackson GD, Connelly A, Duncan JS, et al. Optimizing the diagnosis of hippocampal sclerosis using MR imaging. AJNR Am J Neuroradiol. 1993;14:758–762.
   Web of Science ®Google Scholar
• Pitkänen A, Löscher W, Vezzani A, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15(8):843–856.
   PubMed Web of Science ®Google Scholar
• Labate A, Aguglia U, Tripepi G, et al. Long-term outcome of mild mesial temporal lobe epilepsy: a prospective longitudinal cohort study. Neurology. 2016;86(20):1904–1910.
   PubMed Web of Science ®Google Scholar
• Labate A, Cherubini A, Tripepi G, et al. White matter abnormalities differentiate severe from benign temporal lobe epilepsy. Epilepsia. 2015;56(7):1109–1116.
   PubMed Web of Science ®Google Scholar
• DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029–1035.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Hesdorffer DC, Cascino G, et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia. 2005;46(suppl 11):46–48.
   PubMed Web of Science ®Google Scholar
• Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol. 2006;13:445–450.
   PubMed Web of Science ®Google Scholar
• Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51:251–256.
   PubMed Web of Science ®Google Scholar
• Hu Y, Jiang L, Chen H, et al. Expression of AMPA receptor subunits in hippocampus after status convulsion. Childs Nerv Syst. 2012;28:911–918.
   PubMed Web of Science ®Google Scholar
• Rajasekaran K, Todorovic M, Kapur J. Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol. 2012;72(1):91–102.
   PubMed Web of Science ®Google Scholar
• Prince HC, Tzingounis AV, Levey AI, et al. Functional downregulation of GluR2 in piriform cortex of kindled animals. Synapse. 2000;38(4):489–498.
   PubMed Web of Science ®Google Scholar
• Grooms SY, Opitz T, Bennett MV, et al. Status epilepticus decreases glutamate receptor 2 mRNA and protein expression in hippocampal pyramidal cells before neuronal death. Proc Natl Acad Sci U S A. 2000;97:3631–3636.
   PubMed Web of Science ®Google Scholar
• Pitkänen A, Mathiesen C, Rønn LC, et al. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res. 2007;74(1):45–54.
   PubMed Web of Science ®Google Scholar
• Langer M, Brandt C, Zellinger C, et al. Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology. 2011;61(5–6):1033–1047.
   PubMed Web of Science ®Google Scholar
• Fritsch B, Stott JJ, Joelle Donofrio J, et al. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia. 2010;51(1):108–117.
   PubMed Web of Science ®Google Scholar
• Redecker J, Wittstock M, Benecke R, et al. Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav. 2015;45:176–179.
   PubMed Web of Science ®Google Scholar
• Rohracher A, Höfler J, Kalss G, et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav. 2015;49:354–358.
   PubMed Web of Science ®Google Scholar
• Gill R, Lodge D. Pharmacology of AMPA antagonists and their role in neuroprotection. Int Rev Neurobiol. 1997;40:197–232.
   PubMed Web of Science ®Google Scholar
• Gressens P, Spedding M, Gigler G, et al. The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. Eur J Pharmacol. 2005;519(1–2):58–67.
   PubMed Web of Science ®Google Scholar
• Matucz E, Móricz K, Gigler G, et al. Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats. Brain Res. 2006;1123(1):60–67.
   PubMed Web of Science ®Google Scholar
• Hsieh H, Boehm J, Sato C, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52(5):831–843.
   PubMed Web of Science ®Google Scholar
• Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer’s disease. Mol Neurobiol. 2008;37(1):73–82.
   PubMed Web of Science ®Google Scholar
• Ba M, Kong M, Yu G, et al. GluR1 phosphorylation and persistent expression of levodopa-induced motor response alterations in the Hemi-Parkinsonian rat. Neurochem Res. 2011;36(6):1135–1144.
   PubMed Web of Science ®Google Scholar
• Silverdale MA, Kobylecki C, Hallett PJ, et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse. 2010;64(2):177–180.
   PubMed Web of Science ®Google Scholar
• Rascol O, Barone P, Behari M, et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol. 2012;35(1):15–20.
   PubMed Web of Science ®Google Scholar
• Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s disease. Mov Disord. 2012;27(2):284–288.
   PubMed Web of Science ®Google Scholar
• Silverman JL, Oliver CF, Karras MN, et al. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013;64:268–282.
   PubMed Web of Science ®Google Scholar
• Akamatsu M, Yamashita T, Hirose N, et al. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6:28649.
   PubMed Web of Science ®Google Scholar
• Vossel KA, Tartaglia MC, Nygaard HB, et al. Epileptic activity in Alzheimer’s disease: causes and clinical relevance. Lancet Neurol. 2017;16(4):311–322.
   PubMed Web of Science ®Google Scholar